Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity.
Charbonnel C, Convers-Domart R, Rigaudeau S, Taksin AL, Baron N, Lambert J, Ghez S, Georges JL, Farhat H, Lambert J, Rousselot P, Livarek B. Charbonnel C, et al. Among authors: rousselot p. Eur Heart J Cardiovasc Imaging. 2017 Apr 1;18(4):392-401. doi: 10.1093/ehjci/jew223. Eur Heart J Cardiovasc Imaging. 2017. PMID: 28064155
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.
Larghero J, Leguay T, Mourah S, Madelaine-Chambrin I, Taksin AL, Raffoux E, Bastie JN, Degos L, Berthaud P, Marolleau JP, Calvo F, Chomienne C, Mahon FX, Rousselot P. Larghero J, et al. Among authors: rousselot p. Biochem Pharmacol. 2003 Nov 15;66(10):1907-13. doi: 10.1016/s0006-2952(03)00469-6. Biochem Pharmacol. 2003. PMID: 14599548
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association.
Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, Chantepie S, Gardin C, Rousselot P, Chevret S, Dombret H, Castaigne S. Farhat H, et al. Among authors: rousselot p. Am J Hematol. 2012 Jan;87(1):62-5. doi: 10.1002/ajh.22201. Epub 2011 Nov 10. Am J Hematol. 2012. PMID: 22072535 Free article. Clinical Trial.
False positive galactomannan Platelia due to piperacillin-tazobactam.
Gerlinger MP, Rousselot P, Rigaudeau S, Billon C, Touratier S, Castaigne S, Eloy O. Gerlinger MP, et al. Among authors: rousselot p. Med Mal Infect. 2012 Jan;42(1):10-4. doi: 10.1016/j.medmal.2011.10.018. Epub 2011 Dec 5. Med Mal Infect. 2012. PMID: 22153703
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Ghez D, Micol JB, Pasquier F, Auger N, Saada V, Spentchian M, Ianotto JC, Bourhis JH, Bennaceur-Griscelli A, Terré C, Castaigne S, Rigaudeau S, Rousselot P, de Botton S. Ghez D, et al. Among authors: rousselot p. Eur J Cancer. 2013 Nov;49(17):3666-70. doi: 10.1016/j.ejca.2013.07.147. Epub 2013 Aug 19. Eur J Cancer. 2013. PMID: 23968731
Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.
Sarkozy C, Terré C, Jardin F, Radford I, Roche-Lestienne C, Penther D, Bastard C, Rigaudeau S, Pilorge S, Morschhauser F, Bouscary D, Delarue R, Farhat H, Rousselot P, Hermine O, Tilly H, Chevret S, Castaigne S. Sarkozy C, et al. Among authors: rousselot p. Genes Chromosomes Cancer. 2014 Jan;53(1):106-16. doi: 10.1002/gcc.22123. Epub 2013 Oct 29. Genes Chromosomes Cancer. 2014. PMID: 24249260
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
Pilorge S, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terré C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P. Pilorge S, et al. Among authors: rousselot p. Am J Hematol. 2014 Apr;89(4):399-403. doi: 10.1002/ajh.23653. Epub 2014 Mar 7. Am J Hematol. 2014. PMID: 24375467 Free article.
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Lambert J, Lambert J, Nibourel O, Pautas C, Hayette S, Cayuela JM, Terré C, Rousselot P, Dombret H, Chevret S, Preudhomme C, Castaigne S, Renneville A. Lambert J, et al. Among authors: rousselot p. Oncotarget. 2014 Aug 15;5(15):6280-8. doi: 10.18632/oncotarget.2196. Oncotarget. 2014. PMID: 25026287 Free PMC article. Clinical Trial.
Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion.
Maurizot A, Beressi JP, Manéglier B, de la Marre NH, Spentchian M, Soury P, Solvet-Sebire P, Collet-Gaudillat C, Baud JM, Livarek B, Guilhot F, Rousselot P. Maurizot A, et al. Among authors: rousselot p. Blood Cancer J. 2014 Sep 19;4(9):e247. doi: 10.1038/bcj.2014.66. Blood Cancer J. 2014. PMID: 25238138 Free PMC article. No abstract available.
320 results